[1] Hanic M, Trbojevic-Akmacic I, Lauc G. Inflammatory bowel disease - glycomics perspective[J]. Biochim Biophys Acta Gen Subj, 2019, 1863(10): 1595-1601. [2] Yang MH, Yu J, Chen N, et al. Elevated microRNA-31 expression regulates colorectal cancer progression by repressing its target gene SATB2[J]. PLoS One, 2013, 8(12): e85353-85367. [3] Blasius AL, Beutler B. Intracellular toll-like receptors[J]. Immunity, 2010, 32(3): 305-315. [4] Bing X, Xuelei L, Wanwei D, et al. EGCG maintains Th1/Th2 balance and mitigates ulcerative colitis induced by dextran sulfate sodium through TLR4/MyD88/NF-kappaB signaling pathway in rats[J]. Can J Gastroenterol Hepatol, 2017, 2017: 3057268-3057277. [5] Zhu Y, Gu L, Li Y, et al. miR-148a inhibits colitis and colitis-associated tumorigenesis in mice[J]. Cell Death Differ, 2017, 24(12): 2199-2209. [6] 王 茜, 崔香丽. 白藜芦醇通过下调miR-31-5p的表达抑制细胞增殖[D]. 山西医科大学, 2018: 1-80. [7] 许良中, 杨文涛. 免疫组织化学反应结果的判断标准[J]. 中国癌症杂志, 1996, 4: 229-231. [8] 伍学翠, 赵 云, 李 聪, 等. miRNA在异丙肾上腺素诱导大鼠心肌肥厚中的表达及生物信息学分析[J]. 中国应用生理学杂志, 2019, 35(5): 476-480. [9] Cao B, Zhou X, Ma J, et al. Role of MiRNAs in inflammatory bowel disease[J]. Dig Dis Sci, 2017, 62(6): 1426-1438. [10]Lucas Grzelczyk W, Szemraj J, Kwiatkowska S, et al. Serum expression of selected miRNAs in patients with laryngeal squamous cell carcinoma (LSCC)[J]. Diagn Pathol, 2019, 14(1): 49-57. [11]He J, He J, Min L, et al. Extracellular vesicles transmitted miR-31-5p promotes sorafenib resistance by targeting MLH1 in renal cell carcinoma[J]. Int J Cancer, 2020, 146(4): 1052-1063. [12]Chen G, Feng Y, Li X, et al. Post-transcriptional gene regulation in colitis associated cancer[J]. Front Genet, 2019, 10: 585-598. [13]Cui X, Jin Y, Hofseth AB, et al. Resveratrol suppresses colitis and colon cancer associated with colitis[J]. Cancer Prev Res (Phila), 2010, 3(4): 549-559. [14]Jin Y, Kotakadi VS, Ying L, et al. American ginseng suppresses inflammation and DNA damage associated with mouse colitis[J]. Carcinogenesis, 2008, 29(12): 2351-2359. [15]Klampfer L. Cytokines, inflammation and colon cancer[J]. Curr Cancer Drug Targets, 2011, 11(4): 451-464. [16]Viennois E, Chen F, Merlin D. NF-kappaB pathway in colitis-associated cancers[J]. Transl Gastrointest Cancer, 2013, 2(1): 21-29. [17]Marx J. Cancer research. Inflammation and cancer: the link grows stronger[J]. Science, 2004, 306(5698): 966-968. [18]Papa S, Zazzeroni F, Pham CG, et al. Linking JNK signaling to NF-kappaB: a key to survival[J]. J Cell Sci, 2004, 117(Pt 22): 5197-5208. [19]Simon PS, Sharman SK, Lu C, et al. The NF-kappaB p65 and p50 homodimer cooperate with IRF8 to activate iNOS transcription[J]. BMC Cancer, 2015, 15: 770-782. [20]黄循铷, 王承党, 王瑞幸, 等. 溃疡性结肠炎小鼠肠道通透性改变与TNF-α及NF-κB P65的关系[J]. 中国应用生理学杂志, 2016, 32(2): 112-115. [21]Rashidian A, Muhammadnejad A, Dehpour AR, et al. Atorvastatin attenuates TNBS-induced rat colitis: the involvement of the TLR4/NF-κB signaling pathway[J]. Inflammopharmacology, 2016, 24(2-3): 109-118. [22]Li L, Miao X, Ni R, et al. Epithelial-specific ETS-1 (ESE1/ELF3) regulates apoptosis of intestinal epithelial cells in ulcerative colitis via accelerating NF-κB activation[J]. Immunol Res, 2015, 62(2): 198-212.. [23]Bukholm IK, Nesland JM. Protein expression of p53, p21 (WAF1/CIP1), bcl-2, Bax, cyclin D1 and pRb in human colon carcinomas[J]. Virchows Arch, 2000, 436(3): 224-228. |